Name | 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methylcyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine |
---|---|
Synonyms |
7-(4-fluorobenzyloxy)-2,3-dimethyl-1-[(1S,2S)-2-methylcyclopropylmethyl]pyrrolo[2,3-d]pyridazine
CS-526 |
Description | CS-526 is a potent, selective, reversible and orally active acid pump antagonist. CS-526 inhibits H+,K+-ATPase activity. CS-526 inhibits gastric acid secretion and prevents esophageal lesions. CS-526 has the potential for the research of gastroesophageal reflux disease[1]. |
---|---|
Related Catalog | |
In Vitro | CS-526 (0-100 µM;60 分钟) 抑制 H+ K+-ATP 酶和 Na+ K+ -ATPase 活性呈剂量依赖性,IC50 值分别为 61 nM、10.4 µM[1]。 CS-526 竞争性结合 H+ K+-ATPase 的 K+ 结合位点[1]。 |
In Vivo | CS-526 (1, 3, 10, 30 mg/kg; intraduodenal or p.o.) 以剂量依赖性方式抑制幽门结扎大鼠的胃酸分泌[1]。 CS-526 (1, 3, 10, 30 mg/kg; intrapouch; 180 min) 剂量依赖性地抑制 Heidenhain 袋犬组胺诱导的胃酸分泌[1]。 CS-526 (1, 3, 10, 30 mg/kg; intraduodenal or p.o.) 可预防食管病变和急性胃粘膜病变[1]。 Animal Model: Pylorus-Ligated Rats[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Intraduodenal administration or p.o. Result: Dose-dependently inhibited gastric acid secretion with ID50 values of 2.8, 0.7 mg/kg for intraduodenal administration and oral administration, respectively. Animal Model: Reflux Esophagitis Model in Rats[1] Dosage: 1, 3, 10 mg/kg Administration: Intraduodenal administration or p.o. Result: Significantly reduced the lesion scores with ID50 values of 5.4, 1.9 mg/kg for intraduodenal and p.o. respectively. |
References |
Molecular Formula | C20H22FN3O |
---|---|
Molecular Weight | 339.41 |
Exact Mass | 339.17500 |
PSA | 39.94000 |
LogP | 4.42220 |